CFO Elizabeth Czerepak terminated; Sorrento cuts US workforce from 123 to 90

Sorrento Therapeutics, Inc.

On Nov 3, 2023, Sorrento terminated Elizabeth Czerepak as EVP and CFO, effective immediately.
US headcount reduced from 123 to 90 employees, a 27% cut.
No replacement CFO has been announced; CRO Mohsin Meghji signed the filing.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Elizabeth Czerepak

Executive Vice President and Chief Financial Officer

Sorrento Therapeutics, Inc.

Effective: 2023-11-03
Filed: November 7, 2023, 6:59 PM ET

On November 3, 2023, in connection with the reduction in headcount described below, Sorrento Therapeutics, Inc. (“ Sorrento ” or the “ Company ”) terminated the employment of Elizabeth Czerepak as its Executive Vice President and Chief Financial Officer effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Elizabeth Czerepak was terminated as Executive Vice President and Chief Financial Officer at Sorrento Therapeutics, Inc..

Action: terminated
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

On November 3, 2023, in connection with the reduction in headcount described below, Sorrento Therapeutics, Inc. (“ Sorrento ” or the “ Company ”) terminated the employment of Elizabeth Czerepak as its Executive Vice President and Chief Financial Officer effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-23-115270

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.